Mineralys Therapeutics (MLYS) Competitors

Mineralys Therapeutics logo
$14.16 +0.38 (+2.76%)
Closing price 04:00 PM Eastern
Extended Trading
$14.16 +0.00 (+0.04%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MLYS vs. DFTX, LQDA, OGN, TARS, and ARQT

Should you buy Mineralys Therapeutics stock or one of its competitors? Mineralys Therapeutics's main competitors and comparable companies include Definium Therapeutics (DFTX), Liquidia (LQDA), Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Mineralys Therapeutics compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Mineralys Therapeutics (NASDAQ:MLYS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Definium Therapeutics' return on equity of -53.23% beat Mineralys Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Definium TherapeuticsN/A -53.23% -43.90%
Mineralys Therapeutics N/A -63.26%-56.64%

Definium Therapeutics currently has a consensus price target of $66.29, suggesting a potential upside of 124.88%. Mineralys Therapeutics has a consensus price target of $43.60, suggesting a potential upside of 207.91%. Given Mineralys Therapeutics' higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Definium Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.90
Mineralys Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38

Definium Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definium TherapeuticsN/AN/A-$183.79M-$3.11N/A
Mineralys TherapeuticsN/AN/A-$154.65M-$4.36N/A

In the previous week, Definium Therapeutics had 8 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 10 mentions for Definium Therapeutics and 2 mentions for Mineralys Therapeutics. Definium Therapeutics' average media sentiment score of 0.50 beat Mineralys Therapeutics' score of 0.00 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definium Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mineralys Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Definium Therapeutics beats Mineralys Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Liquidia?

Mineralys Therapeutics (NASDAQ:MLYS) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Liquidia has higher revenue and earnings than Mineralys Therapeutics. Liquidia is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mineralys TherapeuticsN/AN/A-$154.65M-$4.36N/A
Liquidia$158.32M32.21-$68.92M-$1.23N/A

Mineralys Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Mineralys Therapeutics currently has a consensus price target of $43.60, suggesting a potential upside of 207.91%. Liquidia has a consensus price target of $75.23, suggesting a potential upside of 32.93%. Given Mineralys Therapeutics' higher probable upside, equities research analysts plainly believe Mineralys Therapeutics is more favorable than Liquidia.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mineralys Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
Liquidia
1 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.50

Mineralys Therapeutics has a net margin of 0.00% compared to Liquidia's net margin of -15.15%. Liquidia's return on equity of 264.65% beat Mineralys Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mineralys TherapeuticsN/A -63.26% -56.64%
Liquidia -15.15%264.65%44.19%

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Liquidia had 17 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 19 mentions for Liquidia and 2 mentions for Mineralys Therapeutics. Liquidia's average media sentiment score of 0.70 beat Mineralys Therapeutics' score of 0.00 indicating that Liquidia is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mineralys Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Liquidia
3 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Liquidia beats Mineralys Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Organon & Co.?

Mineralys Therapeutics (NASDAQ:MLYS) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Mineralys Therapeutics had 1 more articles in the media than Organon & Co.. MarketBeat recorded 2 mentions for Mineralys Therapeutics and 1 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.13 beat Mineralys Therapeutics' score of 0.00 indicating that Organon & Co. is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mineralys Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Organon & Co.
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Mineralys Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

Mineralys Therapeutics presently has a consensus price target of $43.60, suggesting a potential upside of 207.91%. Organon & Co. has a consensus price target of $12.00, suggesting a potential downside of 13.76%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Mineralys Therapeutics is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mineralys Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
Organon & Co.
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

Organon & Co. has a net margin of 3.49% compared to Mineralys Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 82.06% beat Mineralys Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mineralys TherapeuticsN/A -63.26% -56.64%
Organon & Co. 3.49%82.06%6.03%

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Organon & Co. has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mineralys TherapeuticsN/AN/A-$154.65M-$4.36N/A
Organon & Co.$6.22B0.59$187M$0.7618.31

Summary

Organon & Co. beats Mineralys Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Mineralys Therapeutics (NASDAQ:MLYS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Mineralys Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -102.93%. Tarsus Pharmaceuticals' return on equity of -24.51% beat Mineralys Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tarsus Pharmaceuticals-102.93% -24.51% -12.40%
Mineralys Therapeutics N/A -63.26%-56.64%

Tarsus Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Tarsus Pharmaceuticals has higher revenue and earnings than Mineralys Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus Pharmaceuticals$451.36M8.49-$66.42M-$15.19N/A
Mineralys TherapeuticsN/AN/A-$154.65M-$4.36N/A

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals currently has a consensus price target of $104.57, suggesting a potential upside of 34.64%. Mineralys Therapeutics has a consensus price target of $43.60, suggesting a potential upside of 207.91%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tarsus Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
Mineralys Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 2 mentions for Mineralys Therapeutics. Tarsus Pharmaceuticals' average media sentiment score of 0.28 beat Mineralys Therapeutics' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tarsus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mineralys Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Tarsus Pharmaceuticals beats Mineralys Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Mineralys Therapeutics (NASDAQ:MLYS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Arcutis Biotherapeutics has a net margin of 5.88% compared to Mineralys Therapeutics' net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 14.18% beat Mineralys Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcutis Biotherapeutics5.88% 14.18% 6.28%
Mineralys Therapeutics N/A -63.26%-56.64%

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 2 mentions for Mineralys Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.60 beat Mineralys Therapeutics' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcutis Biotherapeutics
0 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mineralys Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Arcutis Biotherapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Arcutis Biotherapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis Biotherapeutics$376.07M9.14-$16.14M$0.21129.38
Mineralys TherapeuticsN/AN/A-$154.65M-$4.36N/A

84.5% of Mineralys Therapeutics shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arcutis Biotherapeutics presently has a consensus target price of $39.75, suggesting a potential upside of 46.30%. Mineralys Therapeutics has a consensus target price of $43.60, suggesting a potential upside of 207.91%. Given Mineralys Therapeutics' higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than Arcutis Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcutis Biotherapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Mineralys Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38

Summary

Arcutis Biotherapeutics beats Mineralys Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLYS vs. The Competition

MetricMineralys TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.22B$13.35B$7.59B$11.70B
Dividend YieldN/A2.60%2.48%4.65%
P/E RatioN/A26.0931.9526.73
Price / SalesN/A7.098.405.55
Price / CashN/A15.5320.7221.66
Price / Book2.495.304.423.65
Net Income-$154.65M$2.87B$3.51B$394.00M
7 Day Performance-8.65%-5.84%-6.16%-6.39%
1 Month Performance-32.31%-6.83%-7.05%-8.77%
1 Year Performance-66.38%-7.91%-2.52%-8.48%

Mineralys Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLYS
Mineralys Therapeutics
2.5234 of 5 stars
$14.16
+2.8%
$43.60
+207.9%
-68.2%$1.22BN/AN/A76
DFTX
Definium Therapeutics
3.2255 of 5 stars
$34.28
-3.1%
$66.24
+93.2%
+155.2%$4.61BN/AN/A40
LQDA
Liquidia
3.7557 of 5 stars
$50.20
+4.9%
$74.15
+47.7%
+86.8%$4.51B$158.32M36.77216
OGN
Organon & Co.
1.3438 of 5 stars
$13.87
+0.1%
$11.40
-17.8%
+80.4%$3.64B$6.22B18.2410,000
TARS
Tarsus Pharmaceuticals
3.2141 of 5 stars
$73.24
+3.4%
$104.57
+42.8%
-1.3%$3.62B$451.36MN/A370

Related Companies and Tools


This page (NASDAQ:MLYS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners